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Abstract
Background: Pneumonia, and particularly nosocomial (NP) and ventilator-associated pneumonias (VAP), results in
high morbidity and costs. NPs in particular are likely to be caused by Pseudomonas aeruginosa (PA), ~20% of which
in observational studies are resistant to imipenem. We sought to identify the burden of PA imipenem resistance in
pneumonia.
Methods: We conducted a systematic literature review of randomized controlled trials (RCT) of imipenem
treatment for pneumonia published in English between 1993 and 2008. We extracted study, population and
treatment characteristics, and proportions caused by PA. Endpoints of interest were: PA resistance to initial
antimicrobial treatment, clinical success, microbiologic eradication and on-treatment emergence of resistance of
PA.
Results: Of the 46 studies identified, 20 (N = 4,310) included patients with pneumonia (imipenem 1,667, PA 251;
comparator 1,661, PA 270). Seven were double blind, and 7 included US data. Comparator arms included a b-
lactam (17, [penicillin 6, carbapenem 4, cephalosporin 7, monobactam 1]), aminoglycoside 2, vancomycin 1, and a
fluoroquinolone 5; 5 employed double coverage. Thirteen focused exclusively on pneumonia and 7 included
pneumonia and other diagnoses. Initial resistance was present in 14.6% (range 4.2-24.0%) of PA isolates in
imipenem and 2.5% (range 0.0-7.4%) in comparator groups. Pooled clinical success rates for PA were 45.2% (range
0.0-72.0%) for imipenem and 74.9% (range 0.0-100.0%) for comparator regimens. Microbiologic eradication was
achieved in 47.6% (range 0.0%-100.0%) of isolates in the imipenem and 52.8% (range 0.0%-100.0%) in the
comparator groups. Resistance emerged in 38.7% (range 5.6-77.8%) PA isolates in imipenem and 21.9% (range 4.8-
56.5%) in comparator groups.
Conclusions: In the 15 years of RCTs of imipenem for pneumonia, PA imipenem resistance rates are high, and PA
clinical success and microbiologic eradication rates are directionally lower for imipenem than for comparators.
Conversely, initial and treatment-emergent resistance is more likely with the imipenem than the comparator
regimens.
Background
Antimicrobial resistance is a growing concern in the US
and abroad. Among infections caused by gram-positive
pathogens, methicillin-resistant Staphylococcus aureus
(MRSA) has taken center stage, now accounting for well
over 50% of all documented staphylococcal infections in
the US [1]. Similarly, hospitalizations with vancomycin-
resistant enterococcal (VRE) species are rising rapidly,
particularly since 2003 [2,3]. Gram negative bacteria,
though not necessarily rising in volume [3], are also
becoming increasingly resistant to existing antimicro-
bials. Most alarming is the evolution of extended-spec-
trum b-lactamase producing Enterobacteriaceae,a sw e l l
as multidrug resistant Pseudomonas aeruginosa (PA),
some resistant to multiple drug classes [4,5].
PA in particular is reported to have 20% resistance
rates to imipenem, a drug considered to be first-line
therapy for ventilator-associated pneumonia, for exam-
ple, and one that is frequently utilized when the suspi-
cion of PA is high [6]. The patterns of PA resistance are
important to appreciate because of the strong evidence
that inappropriate empiric therapy leads to increased
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infection are less likely to receive appropriate initial
treatment [9,10]. For this reason, starting empiric cover-
age with a broad-spectrum antibiotic followed by de-
escalation has been advocated as a strategy to improve
outcomes [6]. To justify such a strategy it is important
to have complete information on the epidemiology of
pathogen resistance, and in the absence of a national
surveillance mechanism, all potential sources of such
information should be explored. While several primary
epidemiologic and microbiology studies have demon-
strated reduced imipenem susceptibility among PA
[4,5,11,12], the full burden of emerging imipenem resis-
tance reported in the literature has not been quantified.
Thus, we performed a systematic review of literature to
explore and quantify emerging resistance and reduced
susceptibility of PA to imipenem in the setting of
pneumonia.
Methods
We conducted a MEDLINE search using keywords
“pneumonia” and “imipenem” with the Boolean operator
“AND” joining the two. We restricted this search to
papers published in English between January 1993 and
December 2008 that were randomized controlled trials,
clinical trials, or meta-analyses. Two investigators
reviewed all identified studies for relevance and resolved
any disagreement by reaching consensus. Because we
intended to document emerging trends in the develop-
ment and characteristics of imipenem resistance among
PA isolates, only studies utilizing one of the three speci-
fied study designs, including a pharmaceutical compara-
tor, and mentioning both PA and imipenem were
included in our analysis.
Two reviewers (AR, MDZ) extracted pertinent data
from each study and entered it into data extraction
forms developed specifically for the current project. Spe-
cifically, we extracted information about geographic
location of study population, study period, population
characteristics, characterization of therapy, blinding, and
factors related to PA. Although our primary interest was
PA, we documented the intended primary and second-
ary endpoints for each study.
Included were data from all patients with at least 1 PA
isolate receiving at least 1 dose of the specified treat-
ment. We assumed that patients with PA isolates in stu-
dies not specifying a minimum number of antibiotic
doses received at least 1 dose and included them in our
analysis as well. The outcomes of interest were clinical
and microbiological eradication rates for PA among the
included patients, as well as initial and emerging resis-
tance of PA to imipenem and comparator drugs, and
PA superinfection rates. Wherever possible, we normal-
ized both initial and emerging resistance to the baseline
number of patients with PA isolates reported. If it was
unclear whether the newly-emergent resistant PA
occurred in a patient with a previous PA culture, we
assumed that this was the case and utilized the total
number of PA isolates reported in the denominator.
Each patient was assumed to qualify for one initial or
one emergent resistant PA, and thus the words “isolates”
and “patients” are used interchangeably throughout this
report. Finally, we collected information on adverse out-
comes, including development of diarrhea in general
and specifically the emergence of Clostridium difficile
infection (CDI). Studies were excluded if they failed to
report at least one of the outcomes of interest.
The success of PA treatment was computed by deriv-
ing the proportions of clinical and microbiological eradi-
cation across all included studies. We quantified the
pooled overall percentage of PA isolates in which resis-
tance was either present at baseline or emerged, as well
as the incidence of superinfection. All outcome defini-
tions were those used in the respective primary studies;
for example, “clinical success” was defined most fre-
quently as resolution of signs and symptoms related to
the infection. We further performed sensitivity analyses
in studies incorporating blinding in the experimental
protocol, by drug class of the comparator therapy, in
studies with nosocomial pneumonia and those per-
formed in North America only. All pooling was per-
formed qualitatively and no attempt at quantitative
analyses was made.
Results
Of 46 papers identified in our search published between
1993 and 2008, 26 [13-38] were excluded while 20
[39-58] met the inclusion criteria. The reasons for exclu-
sion [13-38] were as follows (Figure 1): no mention of
imipenem (n = 2) [13,14]; study designs other than con-
trolled trials, clinical trials or meta-analyses (n = 4)
[15-18]; failed to mention PA (n = 8) ([9-26]; provided
incomplete quantitative information about PA (n = 2)
[27,28]; quantified the presence of PA isolates but did
not provide useful information about their eradication or
emerging resistance (n = 4) [29-32]; found no PA in
initial cultures (n = 1) [33]. Additionally, 2 controlled
trials assessed the efficacy of alternative imipenem
dosages, and were excluded for this reason [34,35]. To
avoid double counting, we ultimately excluded both of
the meta-analyses [36,37], since all relevant papers exam-
ined therein had already been included, as well as one
additional primary report [38] which duplicated a pre-
viously reported study [57]. One exception was made to
include the study by Shorr and coworkers [44], which is a
subgroup analysis of VAP patients enrolled into another
study of NP in our study set [46]. This was done for the
following reasons: 1). Shorr et al. [44], but not West and
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interest (specifically PA resistance emergence) in the cur-
rent review, 2). Eliminating the Shorr study from the ana-
lyses did not alter the results substantively, and 3).
Several of the sensitivity analyses used only one or the
other of the studies, but not both (see below).
In all, 20 clinical trials comprised the final set [39-58]
(Table 1). Comparator drug subcategories included a b-
lactam arm in 16 studies [39-46,48-51,53,54,56,58],
fluoroquinolone in 5 studies [44,46,47,55,57], aminogly-
coside in 2 studies [53,56], and vancomycin in 1 study
[52]; 6 employed double coverage [44,45,52-54,56]. The
primary outcome for 17 of these 20 studies was clinical
success [39-52,54,57,58] and 16 of 20 included a micro-
biological response assessment for underlying pathogens
[39-43,45-48,50,52-54,56-58] (Table 1). Ten of 20 stu-
dies provided information about the minimum number
of imipenem and comparator doses required for inclu-
sion in analysis, 7 of which included patients if they
received at least 1 dose of either imipenem or the com-
parator [39,41,42,46,47,50,57], and 1 study each exclud-
ing patients receiving fewer than 5 [49], 6 [40], and 15
[55] doses (Table 2).
Seven of 20 studies included patients with mixed
infections (pneumonia and other diagnoses)
[49,50,52-54,56,58], while 13 of the 20 included only
patients with pneumonia [39-48,51,55,57] (Table 1):
seven with NP [39,41,42,44-47], with 3 of those 7 focus-
ing on VAP only [39,44,47]; 4 with community-acquired
pneumonia (CAP) [40,43,48,51], and two with either
CAP or NP [55,57]. Of the 4,310 subjects analyzed in
the 20 studies, 3,328 had pneumonia: 1,667 in the imi-
penem and 1,661 in the comparator groups. Determin-
ing accurately the exact counts of NP and VAP among
the total pneumonia patient population was not feasible.
Among the 4,310 subjects, 521 grew out PA isolates in
microbiological cultures, 251 in the imipenem and 270 in
the comparator groups (Table 2). In 11 studies providing
information about clinical PA outcomes
[39,43,44,46-49,51,52,54,58], 54 of 120 patients in the imi-
penem group and 91 of 121 patients in the comparator
group were considered clinically cured, with the pooled
success rate of 45.2% (range 0.0%-72.0%) for the imipenem
and 74.9% (0.0%-100.0%) for the comparator arms. Simi-
larly, in 11 studies providing information on PA microbio-
logical outcomes [39,40,42,43,46-48,53,54,56,57], 72 of
Figure 1 Study selection flow chart. PA: Pseudomonas aeruginosa; CT: clinical trial; RCT: randomized controlled trial
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nem group were successfully eradicated, while 90 of 171,
52.8% (range 0.0%-100.0%), of isolates in the comparator
group were eliminated. Three studies [39,45,49] reporting
initial PA treatment sensitivities found 12 of 81, 14.6%
(range 4.2%-24.0%) of isolates in the imipenem arm and 2
of 76, 2.5% (range 0.0%-7.4%) of isolates in the comparator
that were resistant to the initial treatment. In 9 studies
reporting the emergence of resistance to the initial antimi-
crobial among PA isolates [39,44,45,47,49,55-58], resis-
tance to imipenem developed in 78 of 202, 38.7% (range
5.6%-77.8%) instances in the imipenem group and 45 of
204, 21.9% (range 4.8%-56.5%) in the comparator treat-
ment group. Data on the rates of PA superinfection could
not be collected reliably. Neither information on average
duration of therapy prior to resistance nor the minimum
inhibitory concentration (MIC) for imipenem was
reported consistently. Although there appeared to be a
directional increase in baseline resistance rate of PA to
imipenem over time (Figure 2), examining treatment-
emergent resistance rates over time did not reveal any
clear directional trends (Figures 3).
While adverse events were reported to some extent in
nearly every study, the attribution of causation to the
respective treatment was rare. Nine of the 21 included stu-
dies reported emergence of diarrhea as an adverse event in
104 of 1,576 patients in the imipenem group, 6.6% (range
2.7%-18.1%), and 145 of 1,563 patients in comparator
group, 9.3% (range 1.0%-29.3%) [39,41,42,45,46,49,50,52,58].
Only 3 of these 9 studies reported CDI emergence, which
was noted in 6 of 334 (1.8%, range 0.0%-5.9%) imipenem-
treated patients and 2 of 335 (0.6%, range 0.0%-1.1%) com-
parator-group patients [45,50,52].
Sensitivity analyses
Blinding
Seven of 20 studies incorporated blinding, 4 of 7 using
double-blinding [42,50,55,57] and 3 using investigator-
blinding only [41,52,58] (Table 3). Only 2 of these 7 stu-
dies [42,57] reported microbiologic eradication of PA,
with the aggregate rate of 29 of 61, 47.8% (range 25.0%-
70.6%) and 34 of 65, 52.1% (range 27.7%-76.5%) in the
imipenem and comparator groups, respectively [42,57].
Further, only 2 of the 7 blinded studies [52,58] provided
information on PA clinical success, where the rates of
this outcome were 3 of 15, 21.1% (range 0.0%-42.1%), in
the imipenem group and 16 of 20, 78.7% (range 75.0%-
82.4%), in the comparator group. While none of the stu-
dies in this group reported baseline resistance rates, in 3
blinded studies reporting emerging resistance [55,57,58],
the rates for this outcome were 38 of 67, 56.9% (range
42.9%-77.8%) and 19 of 75, 25.3% (range 6.3%-41.7%), of
imipenem and comparator group PA isolates,
respectively.
Table 1 Study characteristics.
First author, year Centers Population Primary endpoint Comparator regimen Minimum doses
Chastre, 2008 [39] M VAP C/M success Doripenem 1
Yanagihara, 2005 [40] S CAP C/M success Sulbactam/ampicillin 6
Schmit, 2006 [41] M NP Clinical response Piperacillin/tazobactam 1
Joshi, 2006 [42] M NP Clinical response Piperacillin/tazobactam 1
Romanelli, 2006 [43] M CAP C/M success Meropenem NR
Shorr, 2005 [44] M VAP Clinical success Levofloxacin/ceftazidime NR
Zanetti, 2003 [45] M NP C/M success Cefepime NR
West, 2003 [46] M NP C/M success Levofloxacin/ceftazidime 1
Torres, 2000 [47] M VAP C/M success Ciprofloxacin 1
Bartoloni, 1999 [48] M CAP Clinical response Meropenem
Jaccard, 1998 [49] M Mixed Clinical success Piperacillin/tazobactam 5
Marra*, 1998 [50] S Mixed C/M success, resistance Piperacillin/tazobactam 1
Ho, 1997 [51] NR CAP Clinical success Ceftazidime NR
Raad, 1996 [52] S Mixed C/M success Aztreonam/vancomycin NR
Vic, 1996 [53] S Mixed Bacteriological parameters Ceftazidime/amikacin NR
Bohme, 1995 [54] NR Mixed C/M success Ceftazidime/piperacillin NR
Siami, 1995 [55] M CAP & NP Safety Ciprofloxacin 15
Cometta, 1994 [56] M Mixed Tolerance Imipenem/netilmycin NR
Fink, 1994 [57] M CAP & NP C/M success Ciprofloxacin 1
Norrby, 1993 [58] M Mixed C/M success Ceftazidime NR
M: multicenter, S: single center, NR: not reported, C/M: clinical/microbiological, VAP: ventilator-associated pneumonia, CAP: community-acquired pneumonia, ICU:
intensive care unit, NP: nosocomial pneumonia, NR: not reported, CF: cystic fibrosis, PA: Pseudomonas aeruginosa
*Although this study did not explicitly report on PA outcomes, it was included because it was one of the few studies specifically reporting zero incidence of C.
difficile diarrhea
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PA microbiological eradication rates in studies strati-
fied based on antibiotic class of the comparator drug
mirrored overall PA eradication rates (Table 3). The
pooled rates of clinical success in trials utilizing beta-
lactams and reporting this outcome
[39,43,44,46,48,49,51,52,54,56] were 39.9% (range 0.0%-
72.0%) and 84.7% (0.0%-100.0%) in the imipenem and
comparator groups, with corresponding microbiologic
eradication rates [39,40,42,43,46,48,53,54,56] of 52.7%
Table 2 Results: P. aeruginosa clinical and microbiologic success, baseline and emergent resistance rates*
First author, year Study arm PA isolates
(n)
Clinical success
(%)
Microbiologic eradication
(%)
Resistance at baseline
(%)
Emergent resistance
(%)
Chastre, 2008 [39] Imipenem 25 42.9 35.7 24.0 52.6
Comparator 28 80.0 65.0 0.0 35.7
Yanagihara, 2005
[40]
Imipenem 4 50.0
Comparator 3 0.0
Joshi, 2006 [42] Imipenem 17 70.6
Comparator 18 76.5
Romanelli, 2006
[43]
Imipenem 1 0.0 0.0
Comparator 1 0.0 0.0
Shorr, 2005 [44] Imipenem 18
† 72.0 5.6
Comparator 16 85.0 6.3
Zanetti, 2003 [45] Imipenem 32 15.6 28.1
Comparator 27 7.4 11.1
West, 2003 [46] Imipenem 17
† 41.2 29.4
Comparator 17 64.7 58.8
Torres, 2000 [47] Imipenem 12 66.0 25.0 33.0
Comparator 14 71.0 50.0 7.0
Bartoloni, 1999
[48]
Imipenem 3 66.6 66.7
Comparator 1 100.0 100.0
Jaccard, 1998 [49] Imipenem 24 50.0 4.2 25.0
Comparator 21 90.5 0.0 4.8
Ho, 1997 [51] Imipenem 2 50.0
Comparator 3 100.0
Raad, 1996 [52] Imipenem 1 0.0
Comparator 4 75.0
Vic, 1996 [53] Imipenem 1 100.0
Comparator 19 100.0
Bohme, 1995 [54] Imipenem 3 66.0 66.0
Comparator 0 NA NA
Siami, 1995 [55] Imipenem 9 77.8
Comparator 12 41.7
Cometta, 1994
[56]
Imipenem 24 55.6 33.3
Comparator 23 50.0 56.5
Fink, 1994 [57] Imipenem 44 25.0 50.0
Comparator 47 27.7 28.0
Norrby, 1993 [58] Imipenem 14 42.1 42.9
Comparator 16 82.4 6.3
Pooled rates Imipenem 251 45.2 47.6 14.6 38.7
Comparator 270 74.9 52.8 2.5 21.9
*Limited to studies reporting at least one of these outcomes; empty cells indicate that the corresponding data were not reported
†Although the total pseudomonal isolates in the two arms of each analysis add up to the same number (n = 34), the distribution between the arms is different
presumably due to reclassification of a single PA isolate from the levofloxacin to the imipenem arm, which occurred between the West [46] publication and the
Shorr [44] analysis.
PA:Pseudomonas aeruginosa; NA: not applicable
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0.0%-100.0%) for comparators. Three beta-lactam stu-
dies reported initial resistance rates [39,45,49], and
they were 14.6% (range 4.2%-24.0%) and 2.5% (range
0.0% - 7.4%) for imipenem and comparator groups,
respectively. Resistance emergence was reported in 6
studies [39,44,45,49,56,58] in 31.3% (range 5.6%-52.6%)
of imipenem and 20.1% (range 4.8%-56.5%) of com-
parator group PA isolates. A pooled analysis of the
subgroup of beta-lactam trials specifically comparing
imipenem to another carbapenem revealed clinical suc-
cess rates of 36.5% (range 0.0%-66.7%) in the imipe-
nem and 60.0% (range 0.0%-100.0%) in the comparator
carbapenem groups [39,43,48], while the microbiologic
eradication rates were 39.5% (range 0.0%-66.7%) for
imipenem and 53.8% (range 0.0%-100.0%) for the com-
parator carbapenems [39,43,48,56]. Only one carbape-
nem study reported initial resistance, which was
detected in 24.0% of patients in the imipenem and
0.0% in the doripenem groups [39]. In the same study
comparing doripenem to imipenem in patients with
VAP, the rate of resistance emergence was 52.6% in
the imipenem and 35.7% in the doripenem groups
[39]. This is the only study where resistance emergence
was defined explicitly, and denoted a decrease in sus-
ceptibility being a 4+-fold increase in the MIC [39].
N o t a b l yt r u er e s i s t a n c e( d e f i n e da sM I C≥ 8 μg/mL)
developed in 20% in the doripenem arm and 57% in
the imipenem arm [39]. The only other carbapenem
study reporting emergence of resistance noted this rate
Figure 2 Proportion of initial reported P. aeruginosa resistance to imipenem and comparators graphed chronologically from 1994 to
2009. PA: Pseudomonas aeruginosa
Figure 3 Proportion of treatment-emergent P. aeruginosa resistance to imipenem and comparators graphed chronologically from
1994 to 2009. PA: Pseudomonas aeruginosa
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nem groups [56]. Finally, in the studies comparing imi-
penem to treatment with a fluoroquinolone, imipenem
demonstrated a clinical success rate of 59.7% (range
41.2%-72.0%), while that for the comparators was
73.6% (range 64.7%-85.0%) [44,46,47]. Microbiologic
eradication rates were 26.5% (range 25.0%-29.4%) for
imipenem compared with 45.5% (range 27.7%-58.8%)
in the comparator groups [46,47,57]. While baseline
resistance rates were not reported in any of the fluoro-
quinolone studies, resistance emerged at the rates of
41.6% (range 5.6%-77.8%) in the imipenem and 20.7%
(range 6.3%-41.7%) in the comparator fluoroquinolone
groups [44,47,55,57].
Table 3 Sensitivity analyses*
Subgroup Study
arm
Clinical success Microbiologic eradication Resistance at
baseline
Emergent resistance
PA isolates (n) %
(range)
PA isolates (n) %
(range)
PA
isolates
(n)
%
(range)
PA isolates (n) %
(range)
Blinding
present
I 15 21.1
(0.0-
42.1)
61 47.8
(25.0-
70.6)
NR 67 56.9
(42.9-
77.8)
C 20 78.7
(75.0-
82.4)
65 52.1
(27.7-
76.5)
NR 75 25.3
(6.3-
41.7)
[52,58] [42,57] [55,57,58]
Comparator
drug class
b-lactam I 108 39.9
(0.0-
72.0)
95 52.7
(0.0-
70.6)
81 14.6
(4.2-
24.0)
137 31.3
(5.6-
52.6)
C 107 84.7
(0.0-
100.0)
110 56.3
(0.0-
100.0)
76 2.5
(0.0-
7.4)
131 20.1
(4.8-
56.5)
[39,43,44,46,48,49,51,52,54,56] [39,40,42,43,46,48,53,54,56] [39,45,49] [39,44,45,49,56,58]
Fluoro-
quinolone
I 47 59.7
(41.2-
72.0)
95 26.5
(25.0-
29.4)
NR 83 41.6
(5.6-
77.8)
C 47 73.6
(64.7-
85.0)
110 45.5
(27.7-
58.8)
NR 89 20.7
(6.3-
41.7)
[44,46,47] [46,47,57] [44,47,55,57]
Nosocomial
pneumonia
I 72 55.5
(41.2-
72.0)
71 40.2
(25.0-
50.0)
57 19.9
(4.2-
24.0)
87 29.8
(5.6-
52.6)
C 75 75.2
(64.7-
85.0)
77 62.6
(50.0-
76.5)
55 3.7
(0.0-
7.4)
85 15.0
(6.3-
35.7)
[39,44,46,47] [39,42,46,47] [39,45] [39,44,45,47]
VAP
subgroup
I 60.3
(41.2-
72.0)
30.4
(25.0-
35.7)
25 24.0
(NA)
55 30.4
(5.6-
52.6)
C 78.7
(71.0-
85.0)
57.5
(50.0-
65.0)
28 0.0
(NA)
58 16.3
(6.3-
35.7)
[39,44,47] [39,46] [39] [39,44,47]
North
America only
I 36 37.7
(0.0-
72.0)
78 41.7
(25.0-
70.6)
NR 71 44.4
(5.6-
77.8)
C 37 74.9
(64.0-
85.0)
82 54.3
(27.7-
76.5)
NR 75 25.3
(6.3-
41.7)
[44,46,52] [42,46,57] [44,55,57]
*Numbers in brackets represent corresponding references
PA: Pseudomonas aeruginosa, I: imipenem, C: comparator, NR: not reported, NA: not applicable, VAP: ventilator-associated pneumonia
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In 7 studies enrolling exclusively NP patients, the results
were similar to the overall findings [39,41,42,44-47]
(Table 3). Clinical success in the imipenem arms was
55.5% (range 41.2%-72.0%) and in the comparator arms
75.2% (range 64.7%-85.0%) [39,44,46,47]. Microbiologic
eradication rates were 40.2% (range 25.0%-50.0%) in the
imipenem and 62.6% (range 50.0%-76.5%) in the com-
parator groups [39,42,46,47]. In the 2 studies reporting
b a s e l i n er e s i s t a n c et h i sr a t ew a s1 9 . 9 %( r a n g e4 . 2 % -
24.0%) in the imipenem and 3.7% (range 0.0%-7.4%) in
the comparator groups [39,45]. Four studies in this sub-
group reported resistance emergence, and these pooled
rates were 29.8% (range 5.6%-52.6%) in the imipenem
and 15.0% (range 6.3%-35.7%) in the comparator groups
[39,44,45,47]. A further look at VAP patients only
revealed similar rates of 60.3% (range 41.2%-72.0%) and
78.7% (range 71.0%-85.0%) imipenem and comparator
clinical success rates, respectively [39,44,47], while the
corresponding microbiologic eradication rates for imipe-
nem and comparators were 30.4% (range 25.0%-35.7%)
and 57.5% (range 50.0%-65.0%) [39,46].
Geographic location
The final sensitivity analysis was confined to the stu-
dies conducted only in North America
[42,44,46,50,52,55,57]. In the 3 studies in this group
reporting clinical success, the pooled rates of clinical
success were 37.7% (range 0.0%-72.0%) and 74.9%
(range 64.0%-85.0%) for the imipenem and comparator
groups, respectively [44,46,52]. The corresponding
microbiologic eradication rates were 41.7% (range
25.0%-70.6%) in the imipenem and 54.3% (range
27.7%-76.5%) in the comparator groups [42,46,57].
While none of the North American studies reported
baseline resistance rates, resistance emerged in 44.4%
(range 5.6%-77.8%) of imipenem and 25.3% (range
6.3%-41.7%) of comparator group isolates [44,55,57].
Discussion
The current systematic review confirms clinical experi-
ence that many PA isolates are likely to be resistant to
imipenem at the initiation of treatment and, impor-
tantly, are likely to develop treatment-emergent resis-
tance. Not only does PA account for 12% of all reported
pathogens in pneumonia, 14.6% of all PA isolates exhibit
resistance to imipenem at the initiation of treatment,
and an additional 38.7% develop this during the course
of treatment with imipenem. For comparator interven-
tions, these rates are directionally lower, albeit still sub-
stantial, with 2.5% initial and 21.9% emergent resistance.
While directionally slightly higher for both imipenem
and comparator arms in the trials employing blinding,
these general rates persisted across all sensitivity
analyses.
As antibiotic resistance continues to escalate among
both gram-positive and gram-negative pathogens [1,3-5],
for PA specifically, a recent survey from the National
Nosocomial Infections Surveillance Network [4]
reported year 2003 PA resistance rates of approximately
32%, 20% and 30% to third generation cephalosporins,
imipenem and quinolones, respectively, representing
20%, 15% and 9% growth, respectively, over the average
resistance rates observed between 1998 and 2002 [4].
The importance of this development cannot be over-
stated for several reasons. First, it is clear that, similar to
other resistant infections, multidrug resistant PA confers
worsenes hospital outcomes, including increased mortal-
ity, prolonged length of stay and a rise in costs [59-61].
Second, and key to these outcomes at least in part, is
the fact that a patient infected with a resistant pathogen
is far more likely to be treated with an inappropriate
initial antibiotic (one to which the isolate does not exhi-
bit sensitivity in vitro) than with an appropriate one, a
choice that approximately doubles the patient’sr i s ko f
death [9,10]. Third, the rapid evolution of antimicrobial
resistance is outpacing efforts to develop and manufac-
ture newer therapies that are effective against new
pathogens [62,63]. For all these reasons, and most
importantly to improve patient-level outcomes, the pat-
terns of antimicrobial resistance remain critical to study,
and this current effort adds to the epidemiologic and
microbiology-based knowledge of the burden of PA
resistance to imipenem.
The rates of imipenem resistance among PA we
uncovered were higher than the 20% reported by the
NNIS in year 2003; ours approached 15% at baseline
and developed on treatment in a further 39% of the iso-
lates [4]. The differences between the two sources most
likely represent differences in populations, in case defi-
nitions and in sampling methods. Although neither
source is completely generalizable to real-world practice,
(trials usually represent a highly select population and
the composition of the NNIS hospitals is not disclosed
and may not be representative of the US institutions
overall) both sources confirm that the problem is grave.
Interestingly, similar to the NNIS data, we observed an
increase in the prevalence of baseline, but not emergent
Pseudomonal imipenem resistance over time (Figure 1).
Our study has additionally documented substantial
rates of emergent PA resistance while on treatment, par-
ticularly with imipenem. This result echoes the data
reported in the meta-analysis by Siempos and collea-
gues, where development ofr e s i s t a n c eb yP Ad u r i n g
treatment for nosocomial pneumonia was higher in
patients on carbapenems (mainly imipenem) than other
antimicrobials, and that carbapenems were associated
with lower treatment success when compared to other
antimicrobials [64].
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confirming epidemiologic observations, our study
further suggested that there is an opportunity to use
ongoing pooled analyses of clinical data to understand
antibiotic resistance issue as an adverse event. Because
no individual study is likely to be powered to detect sig-
nificant rates of baseline or emergent resistance, phar-
macoepidemiologic surveillance methods should be
advocated to quantify significant trends in this outcome.
These techniques can be used as validation strategies for
data obtained in epidemiologic and microbiology-based
studies. Furthermore, our data point to the need to use
integrated databases that include pharmacy and labora-
tory data as well for ongoing monitoring of antimicro-
bial resistance among specific organisms, such as PA.
Our study had a number of limitations, most of them
driven by the limitations of either design or reporting of
the primary trials. First, not all studies allowed us to
extract data pertaining only to pneumonia patients, and
therefore a small proportion of the overall aggregate
results does not pertain to this disease. To counterba-
lance this issue, we performed a sensitivity analysis
among patients with only nosocomial pneumonia, and
the results in this group were not substantively different
from those in the overall population. Second, despite
the aggregate sample size of over 4,000 subjects with
pneumonia, the subgroup growing out Pseudomonal
pathogens was small, accounting for 12% of all cases.
Furthermore, since not all endpoints of interest were
reported in every study, the number of PA isolates con-
tinued to drift lower in specific analyses, lending limited
power for drawing firm conclusions. For this reason,
and due to inherent limitation of the data (i.e., PA was
n e v e rt h ep r i m a r yf o c u so ft h es t u d y )w ed i dn o t
attempt to perform statistical testing. Nevertheless, the
fact that most sensitivity analyses resulted in similar
proportions of resistance detection lends further cred-
ibility to the numbers. It is worth underscoring that
some of the ranges of clinical and microbiologic
response rates went from 0.0% to 100.0% (Tables 2, 3),
the width of the range ostensibly reducing the useful-
ness of our observation. However, we must point out
that four of the five studies reporting these rates each
included only one pseudomonal isolate [43,48,51-53],
making these estimates neither clinically nor statistically
meaningful. Excluding these rates from the clinical suc-
cess endpoint, for example, would result in the range
from 41.2% to 72.0% in the imipenem and from 64.7%
to 90.5% for the comparator groups (Table 2). Third,
only a handful of the trials employed blinding to reduce
bias, and in those trials the resistance rates were direc-
tionally slightly higher than in ones without blinding.
Despite these limitations, this body of evidence further
served to call attention to the alarming rates of
antimicrobial resistance among PA in general, and to
imipenem specifically.
Conclusions
In summary, pooling observations from clinical trials
occurring over a 15-year period we computed the cumu-
lative PA resistance rate to imipenem to be in the range
of 50%, persisting in many sensitivity analyses. The 15%
resistance rate at baseline further stresses the impor-
tance of risk stratification at bedside and the need to
employ early appropriate therapy to improve patient
outcomes. The additional 39% resistance development
on treatment is also sobering, implying that 1) clinicians
employing early broad spectrum coverage need to pay
exquisite attention to prompt de-escalation if such cov-
erage is not needed, and 2) researchers need to focus on
developing novel therapies whose mechanisms of action
may be less subject to the microbial adaptation appara-
tus. In all, our data add to the epidemiologic alarm of
PA resistance and help further sound the call to arrive
at strategies that balance patient outcomes with the
growing public health threat of antimicrobial resistance.
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